Publication: 0
Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: In vitro and ex vivo functionality studies in corneal epithelial cells
Loading...
Full text at PDC
Publication Date
2017-01
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citations
Exportar
Abstract
In ocular surface inflammatory diseases, such as dry eye disease, long-term symptom relief requires targeting the inflammation itself rather than treating only the surface-associated dryness with artificial tears. Therefore, we included an anti-inflammatory agent in an unpreserved liposome-based (LP) formulation used as artificial tears. Our aim was to characterize and study its in vitro and ex vivo cell uptake and functionality. Human corneal epithelial (HCE) cells were used to study MPA-LP37 induced effects after 60 min of exposure, using blank LP and non-LP MPA formulations as controls. A fluorescent labeled LP formulation was used to determine uptake by HCE cells and localization in ex vivo porcine corneas. The LP formulation complied with the required physicochemical properties and had no cytotoxicity on HCE cells after 60 min of exposure. HCE cells showed LP-associated fluorescence at 24, 48, and 72 h after 60 min of exposure, and the LP-associated fluorescence was uniformly distributed throughout the porcine corneal epithelium immediately after 5 min of exposure. MPA44 LP increased protein expression and nuclear translocation of progesterone receptor in comparison with controls as determined by Western blotting and immunofluorescence. Moreover, MPA-LP significantly reduced the cell proliferation rate and IL-6 and IL-8 production 48 h after the exposure period, as determined by the alamarBlue assay and ELISA, respectively. None of these effects were evident in blank LP-exposed cells and non-LP MPA formulation reduced only IL-6 production. Our results suggest that the LP50 based formulation, used to replenish the lipids of the tear film, can be loaded with anti-inflammatory agents that can be delivered into the cells and activate specific drug receptors. These agents can reduce inflammatory cytokine production and may be effective in the treatment of inflammatory processes associated with ocular surface diseases.
Description
UCM subjects
Unesco subjects
Keywords
Citation
Ali Y., Lehmussaari K., 2006. Industrial perspective in ocular drug delivery. Adv. Drug Deliv. Rev. 58, 1258-1268.
Ammar H.O., Salama H.A., Ghorab M., Mahmoud A.A., 2009. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech 10, 808-819.
Araki-Sasaki K., Ohashi Y., Sasabe T., Hayashi K., Watanabe H., Tano Y., Handa H., 1995. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest. Ophthalmol. Vis. Sci. 36, 614-621.
Baudouin C., Labbe A., Liang H., Pauly A., Brignole-Baudouin F., 2010. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res. 29, 312-334.
Cejkova J., Ardan T., Cejka C., Luyckx J., 2011. Favorable effects of trehalose on the development of UVB-mediated antioxidant/pro-oxidant imbalance in the corneal epithelium, proinflammatory cytokine and matrix metalloproteinase induction, and heat shock protein 70 expression. Graefes Arch. Clin. Exp. Ophthalmol. 249, 1185-1194.
Cops E.J., Bianco-Miotto T., Moore N.L., Clarke C.L., Birrell S.N., Butler L.M., Tilley W.D., 2008. Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J. Steroid Biochem. Mol. Biol. 110, 236-243.
Davies N.M., 2000. Biopharmaceutical considerations in topical ocular drug delivery. Clin. Exp. Pharmacol. Physiol. 27, 558-562.
Di Tommaso C., Bourges J.L., Valamanesh F., Trubitsyn G., Torriglia A., Jeanny J.C., Behar-Cohen F., Gurny R., Moller M., 2012. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Eur. J. Pharm. Biopharm. 81, 257-264.
Diebold Y., Calonge M., 2010. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res. 29, 596-609.
Duzgune&scedil, N., Nir S., 1999. Mechanisms and kinetics of liposome-cell interactions. Adv. Drug Deliv. Rev. 40, 3-18.
Ekstrand-Hammarstrom B., Osterlund C., Lilliehook B., Bucht A., 2007. Vitamin E down-modulates mitogen-activated protein kinases, nuclear factor-kappaB and inflammatory responses in lung epithelial cells. Clin. Exp. Immunol. 147, 359-369.
Elisia I., Kitts D.D., 2015. Tocopherol isoforms (alpha-,gamma-, and delta-) show distinct capacities to control Nrf-2 and NfkappaB signaling pathways that modulate inflammatory response in Caco-2 intestinal cells. Mol. Cell. Biochem. 404, 123-131.
Enriquez-de-Salamanca A., Calder V., Gao J., Galatowicz G.,
Garcia-Vazquez C., Fernandez I., Stern M.E., Diebold Y., Calonge M., 2008. Cytokine responses by conjunctival epithelial cells: an in vitro model of ocular inflammation. Cytokine 44, 160-167.
Hathout R.M., Mansour S., Mortada N.D., Guinedi A.S., 2007. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech 8, 1.
Joffre C., Leclere L., Buteau B., Martine L., Cabaret S., Malvitte L., Acar N., Lizard G., Bron A., Creuzot-Garcher C., Bretillon L., 2007. Oxysterols induced inflammation and oxidation in primary porcine retinal pigment epithelial cells. Curr. Eye Res. 32, 271-280.
Lam H., Bleiden L., de Paiva C.S., Farley W., Stern M.E., Pflugfelder S.C., 2009. Tear cytokine profiles in dysfunctional tear syndrome. Am. J. Ophthalmol. 147, 198-205. e1.
Law S.L., Huang K.J., Chiang C.H., 2000. Acyclovir containing liposomes for potential ocular delivery. Corneal penetration and absorption. J. Control. Release 63, 135-140.
Lee K.D., Nir S., Papahadjopoulos D., 1993. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 32, 889-899.
Li J., Roubeix C., Wang Y., Shi S., Liu G., Baudouin C., Chen W., 2012. Therapeutic efficacy of trehalose eye drops for treatment of murine dry eye induced by an intelligently controlled environmental system. Mol. Vis. 18, 317-329.
Lim A., Wenk M.R., Tong L., 2015. Lipid-Based Therapy for Ocular Surface Inflammation and Disease. Trends Mol. Med. .
Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M., 1995. The nuclear receptor superfamily: the second decade. Cell 83, 835-839.
Massingale M.L., Li X., Vallabhajosyula M., Chen D., Wei Y., Asbell P.A., 2009. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 28, 1023-1027.
Patel A., Cholkar K., Agrahari V., Mitra A.K., 2013. Ocular drug delivery systems: An overview. World J. Pharmacol. 2, 47-64.
Pflugfelder S.C., Solomon A., Stern M.E., 2000. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 19, 644-649.
Pinto-Bonilla J.C., Del Olmo-Jimeno A., Llovet-Osuna F., Hernandez-Galilea E., 2015. A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye 590 syndrome. Ther. Clin. Risk Manag. 11, 595-603.
Purslow C., Wolffsohn J.S., 2005. Ocular surface temperature: a review. Eye Contact Lens 31, 117-123.
Rodriguez I.R., Larrayoz I.M., 2010. Cholesterol oxidation in the retina: implications of 7KCh formation in chronic inflammation and age-related macular degeneration. J. Lipid Res. 51, 2847-2862.
Schaeffer H.E., Krohn D.L., 1982. Liposomes in topical drug delivery. Invest. Ophthalmol. Vis. Sci. 22, 220-227.
Shabir G.A., 2003. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J. Chromatogr. A 987, 57-66.
Sitruk-Ware R., 2004. Pharmacological profile of progestins. Maturitas 47, 277-283.
Sutherland R.L., Hall R.E., Pang G.Y., Musgrove E.A., Clarke C.L., 1988. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res. 48, 5084-5091.
Treede I., Braun A., Jeliaskova P., Giese T., Fullekrug J., Griffiths G., Stremmel W., Ehehalt R., 2009. TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol. 9, 53- 230X-9-53.
Vicario-de-la-Torre M., Benitez-del-Castillo J.M., Vico E., Guzman M., de-Las-Heras B., Herrero-Vanrell R., Molina-Martinez I.T., 2014. Design and characterization of an ocular topical liposomal preparation to replenish the lipids of the tear film. Invest. Ophthalmol. Vis. Sci. 55, 7839-7847.
Zhou H., Kimura K., Orita T., Nishida T., Sonoda K.H., 2012. Inhibition by medroxyprogesterone acetate of interleukin-1beta-induced collagen degradation by corneal fibroblasts. Invest. Ophthalmol. Vis. Sci. 53, 4213-4219.